Literature DB >> 8081637

The cost of epilepsy in patients attending a specialist epilepsy service.

R J Swingler1, D L Davidson, R C Roberts, F Moulding.   

Abstract

Epilepsy is a common disability, especially in young adults, and, as the costs to the community are likely to be high, estimates are required to plan health and community care. The neurological unit of Dundee Royal Infirmary provides an epilepsy clinic for the Tayside region (population 300,000) and in 1991 the records of over 303 patients were computerized using the Epicare system developed by Sanofi-Winthrop. It was calculated that the total state expenditure on care was 662,919 pounds (2188 pounds/head) in 1991. The direct health costs were obtained by reviewing database entries and medical records and were estimated to be 159,192 pounds (24%), including 77,171 pounds for drugs, 64,750 pounds for hospital care and 17,271 pounds for general practice consultations. The cost of welfare payments was 503,728 pounds/year (76%) (4419 pounds/recipient). The transfer payments to patients with epilepsy greatly exceed the costs of health care and any management strategy which improves the prospects for employment and independence of people with epilepsy is likely to produce significant fiscal benefits for both the individual and the state.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8081637     DOI: 10.1016/s1059-1311(05)80201-8

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  8 in total

1.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

Review 2.  The costs of epilepsy and cost-based evaluations of anticonvulsants.

Authors:  W G Johnson
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

Review 3.  Impediments to the diffusion of innovative medicines in Europe.

Authors:  Oliver Schöffski
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Cost-of-illness of epilepsy in Italy. Data from a multicentre observational study (Episcreen).

Authors:  P Berto; P Tinuper; S Viaggi
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

Review 5.  Utilization and costs of antiepileptic drugs in the elderly: still an unsolved issue.

Authors:  Massimiliano Beghi; Rodolfo Savica; Ettore Beghi; Alessandro Nobili; Livio Garattini
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 6.  Cost of epilepsy: a systematic review.

Authors:  Adam Strzelczyk; Jens Peter Reese; Richard Dodel; Hajo M Hamer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

7.  The size, burden and cost of disorders of the brain in the UK.

Authors:  Naomi A Fineberg; Peter M Haddad; Lewis Carpenter; Brenda Gannon; Rachel Sharpe; Allan H Young; Eileen Joyce; James Rowe; David Wellsted; David J Nutt; Barbara J Sahakian
Journal:  J Psychopharmacol       Date:  2013-07-24       Impact factor: 4.153

Review 8.  Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples.

Authors:  Lan Gao; Hao Hu; Fei-Li Zhao; Shu-Chuen Li
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.